Independent Study Shows Significant Decline in Cardiac Device Infections with TYRX® Antibacterial Envelope

News | 05. 10. 2013


New Data in High Risk Patients Presented at Heart Rhythm Society
Shows a 70% Reduction in CIED Infections

Denver, CO (May 10, 2013): Use of TYRX, Inc.’s AIGISRx® Antibacterial Envelope significantly reduced device infection rates in patients at high risk for device infection who received cardiovascular implantable electronic device (CIED) implants, according to a study presented today at Heart Rhythm 2013, the Heart Rhythm Society’s 34th Annual Scientific Sessions.